TuberculosisNCT02076139
Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis
A study testing Nyaditum resae® 10e4, Nyaditum resae® 10e5 and Distilled water in people with Tuberculosis, run by Manresana de Micobacteriologia, SL at 1 site in Spain.
Trial summary
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Regulatory T cells (Treg) memory cells one week after the first administration and the global… Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Tuberculosis
- What is being tested?
- Nyaditum resae® 10e4, Nyaditum resae® 10e5 and Distilled water
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 47 participants
- Where
- 1 siteSpain
- Study dates
- Mar 2014to Jul 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Informed consent before starting the selection process.
- Women and men ≥ 18 years.
- Availability to meet the requirements of the protocol.
Who cannot join
- HIV positive.
- Known immunodeficiencies.
- Pregnancy and maternal lactation.
- Active tuberculosis.
- Enrollment in another clinical trial.
- Chronic administration of: methotrexate, azathioprine, cyclophosphamide, oral corticosteroids and other immunosuppressive therapies / immunomodulatory .
Show all 9Show fewer
- Administration of blood products or blood derivatives during the 6 months prior to randomization.
- Detection by the researcher lack of knowledge or willingness to participate and fulfill all the requirements of the protocol.
- Any other finding that the investigator's opinion, could jeopardize the performance of the protocol or significantly influence the results or interpretation of the effects of probiotic.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Regulatory T cells (Treg) memory cells one week after the first administration and the global tolerability of the treatment. Nyaditum resae® is a preparation in the form of drinkable vials containing heat-killed environmental mycobacteria. The overall objective of the study is the effect of Nyaditum resae® on immunity, which could reduce the risk of developing active tuberculosis.
Read the detailed description
The incidence of tuberculosis is still a problem of the first magnitude. Every year 1.5 million people die; there are 10 million cases of illness and 100 million new infected. The growing problem of multiresistance is to be added, remaining so prevalent: 700,000 patients, a figure that increases annually with 100,000 people. Prevention of tuberculosis is currently very difficult because it is a disease caused by a bacillus (Mycobacterium tuberculosis) that is transmitted by air: No risk factor for becoming infected has been identified and there is still no prophylactic vaccine that prevents from infection. One of the most characteristic aspects of tuberculosis is that the majority (90-95 %) of people without immunity alterations do not develop the disease after being infected. As for people who do develop the disease, it is still not known why they develop it.
A group of researchers from the Institut Germans Trias i Pujol recently discovered a mechanism that explains this trend. In short, what happens is that certain people create a too strong inflammatory response against tuberculosis bacillus, which ends up creating massive destruction of the tissue that is around the bacillus and brings the characteristic lesion of tuberculosis: tuberculous cavity.
This group of researchers was devising ways to "reeducate" the immune system against the bacillus not make it aggressive. And they did it using two instruments. The first one, an environmental mycobacteria, namely a bacillus of the family of mycobacteria tuberculosis, that usually lives in the water they drink, so that at a greater or lesser extent the investigators already have it in their intestinal flora. The second, inducing a tolerant response, like the investigators do when they eat food. To induce a tolerant response, low and repeated doses of the product make the immune system of the digestive duct "used to" their presence. Thus, when it becomes to find the product, the immune system reacts in a very light and balanced manner, avoiding excessive inflammatory responses. The clearest example is the fact that their immune system "is used" to feed proteins and generates no rejection answers found in the intestinal mucosa.
Hence comes the probiotic Nyaditum resae®, a preparation in the form of drinkable vials, containing a heat-killed environmental mycobacteria and thus can generate a cross-immunity with the tuberculosis bacillus. By giving low and repeated dose to generate a tolerant response, which happens when there is an infection by Mycobacterium tuberculosis, so that a balanced immune response is triggered able to reduce the risk of developing active tuberculosis.
- Conditions
- Tuberculosis
- Being tested
- Nyaditum resae® 10e4, Nyaditum resae® 10e5, Distilled water
- Keywords
- tuberculosis, treg, tolerance, probiotic, mycobacteria
- Medical subject headings
- Tuberculosis, Mycobacterium Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nyaditum resae® 10e4Dietary supplement
Nyaditum resae® 10e5Dietary supplement
Distilled waterOther
| Study group | Role | What they receive |
|---|---|---|
| Nyaditum resae® 10e4 | Experimental | The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®. Receives: Dietary Supplement: Nyaditum resae® 10e4 |
| Nyaditum resae® 10e5 | Experimental | The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®. Receives: Dietary Supplement: Nyaditum resae® 10e5 |
| Placebo | Placebo comparator | The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days. Receives: Other: Distilled water |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Specific Treg memory cells at week 1
Median increase of specific Treg memory cells at week 1.
Measured: From Baseline to Week 1
Global tolerability of Nyaditum resae ®, proportion of participants with adverse events related to study treatment.
Proportion of patients presenting adverse events related to study treatment.
Measured: Baseline to week 6
Secondary outcomes (4)
Local tolerability (gastrointestinal duct), proportion of participants with gastrointestinal adverse events related to study treatment.
Proportion of participants presenting gastrointestinal adverse events related to study treatment.
Measured: Baseline to week 6
Systemic tolerability (vital signs, physical exam, laboratory tests), proportion of participants with systemic adverse events related to study treatment.
Proportion of participants presenting systemic adverse events related to study treatment.
Measured: Baseline to week 6
Change from Baseline in Specific Treg memory cells at week 2
Median increase of specific Treg memory cells at week 2.
Measured: From Baseline to Week 2
Change from Baseline in Specific Treg memory cells at month 12
Median increase of specific Treg memory cells at month 12
Measured: From Baseline to Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2014 (estimated)
- Study startMar 2014
- Primary completionJun 2014
- Study completionJul 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for TuberculosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- Manresana de Micobacteriologia, SL
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Eva Montané, MD, PhD, Principal investigator, Germans Trias i Pujol Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02076139
- Sponsor's protocol ID
- NYADATREG
- Status last verified
- Sep 2017
- First submitted
- 20 Feb 2014
- Last updated
- 31 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
Publications
Tukvadze N, Cardona P, Vashakidze S, Shubladze N, Avaliani Z, Vilaplana C, Cardona PJ. Development of the food supplement Nyaditum resae as a new tool to reduce the risk of tuberculosis development. Int J Mycobacteriol. 2016 Dec;5 Suppl 1(Suppl 1):S101-S102. doi: 10.1016/j.ijmyco.2016.09.073. Epub 2016 Nov 14.
PubMed 28043488
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection
- ClinicalTrials.gov ID
- NCT02076139
- Acronym / sponsor ID
- NYADATREG
- Conditions
- Tuberculosis
- Keywords
- tuberculosis, treg, tolerance, probiotic, mycobacteria
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- Manresana de Micobacteriologia, SLIndustry (pharma, biotech, devices)
- Study start
- Mar 2014
- Primary completion
- Jun 2014 (actual)
- Study completion
- Jul 2015 (actual)
- First posted
- 3 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Regulatory T cells (Treg) memory cells one week after the first administration and the global tolerability of the treatment. Nyaditum resae® is a preparation in the form of drinkable vials containing heat-killed environmental mycobacteria. The overall objective of the study is the effect of Nyaditum resae® on immunity, which could reduce the risk of developing active tuberculosis.
Detailed description
The incidence of tuberculosis is still a problem of the first magnitude. Every year 1.5 million people die; there are 10 million cases of illness and 100 million new infected. The growing problem of multiresistance is to be added, remaining so prevalent: 700,000 patients, a figure that increases annually with 100,000 people. Prevention of tuberculosis is currently very difficult because it is a disease caused by a bacillus (Mycobacterium tuberculosis) that is transmitted by air: No risk factor for becoming infected has been identified and there is still no prophylactic vaccine that prevents from infection. One of the most characteristic aspects of tuberculosis is that the majority (90-95 %) of people without immunity alterations do not develop the disease after being infected. As for people who do develop the disease, it is still not known why they develop it.
A group of researchers from the Institut Germans Trias i Pujol recently discovered a mechanism that explains this trend. In short, what happens is that certain people create a too strong inflammatory response against tuberculosis bacillus, which ends up creating massive destruction of the tissue that is around the bacillus and brings the characteristic lesion of tuberculosis: tuberculous cavity.
This group of researchers was devising ways to "reeducate" the immune system against the bacillus not make it aggressive. And they did it using two instruments. The first one, an environmental mycobacteria, namely a bacillus of the family of mycobacteria tuberculosis, that usually lives in the water they drink, so that at a greater or lesser extent the investigators already have it in their intestinal flora. The second, inducing a tolerant response, like the investigators do when they eat food. To induce a tolerant response, low and repeated doses of the product make the immune system of the digestive duct "used to" their presence. Thus, when it becomes to find the product, the immune system reacts in a very light and balanced manner, avoiding excessive inflammatory responses. The clearest example is the fact that their immune system "is used" to feed proteins and generates no rejection answers found in the intestinal mucosa.
Hence comes the probiotic Nyaditum resae®, a preparation in the form of drinkable vials, containing a heat-killed environmental mycobacteria and thus can generate a cross-immunity with the tuberculosis bacillus. By giving low and repeated dose to generate a tolerant response, which happens when there is an infection by Mycobacterium tuberculosis, so that a balanced immune response is triggered able to reduce the risk of developing active tuberculosis.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Nyaditum resae® 10e4 | Experimental | Dietary Supplement: Nyaditum resae® 10e4The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®. |
| Nyaditum resae® 10e5 | Experimental | Dietary Supplement: Nyaditum resae® 10e5The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®. |
| Placebo | Placebo comparator | Other: Distilled waterThe subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Informed consent before starting the selection process.
- Women and men ≥ 18 years.
- Availability to meet the requirements of the protocol.
Key exclusion criteria (9 listed)
- HIV positive.
- Known immunodeficiencies.
- Pregnancy and maternal lactation.
- Active tuberculosis.
- Enrollment in another clinical trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nyaditum resae® 10e4 | Dietary supplement | Nyaditum resae® 10e4 |
| Nyaditum resae® 10e5 | Dietary supplement | Nyaditum resae® 10e5 |
| Distilled water | Other | Placebo |
Primary outcome
Change from Baseline in Specific Treg memory cells at week 1
Time frame: From Baseline to Week 1
Median increase of specific Treg memory cells at week 1.
Global tolerability of Nyaditum resae ®, proportion of participants with adverse events related to study treatment.
Time frame: Baseline to week 6
Proportion of patients presenting adverse events related to study treatment.
4 secondary outcomes
Local tolerability (gastrointestinal duct), proportion of participants with gastrointestinal adverse events related to study treatment.
Time frame: Baseline to week 6
Systemic tolerability (vital signs, physical exam, laboratory tests), proportion of participants with systemic adverse events related to study treatment.
Time frame: Baseline to week 6
Change from Baseline in Specific Treg memory cells at week 2
Time frame: From Baseline to Week 2
Change from Baseline in Specific Treg memory cells at month 12
Time frame: From Baseline to Month 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2018.
- Derived from this study: PubMed 28043488Tukvadze N, Cardona P, Vashakidze S, Shubladze N, Avaliani Z, Vilaplana C, Cardona PJ. Development of the food supplement Nyaditum resae as a new tool to reduce the risk of tuberculosis development. Int J Mycobacteriol. 2016 Dec;5 Suppl 1(Suppl 1):S101-S102. doi: 10.1016/j.ijmyco.2016.09.073. Epub 2016 Nov 14.
Related trials for Tuberculosis
RecruitingPhase 4
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
Mycobacterium Avium Complex Pulmonary Disease
RecruitingObservational study
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Tuberculosis
Not yet recruitingPhase 2
Re-evaluating the Duration in Children of TB Treatment
Tuberculosis
RecruitingPhase 1/2
A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV
Tuberculosis
Active, not recruitingPhase 3
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
Tuberculosis, MDR
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eva Montané, MD, PhD principal investigator
Germans Trias i Pujol Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nyaditum resae® 10e4, Nyaditum resae® 10e5 and Distilled water in people with Tuberculosis, run by Manresana de Micobacteriologia, SL at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Specific Treg memory cells at week 1 (time frame: From Baseline to Week 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02076139, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2018.